Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

Novo Nordisk A/S ADR (NVO), a trailblazer in the weight-loss revolution, has endured a bruising 2025. The Danish pharma giant has been hit by trimmed growth forecasts, pricing pressure, rising competition from Eli Lilly (LLY), mass layoffs, dramatic leadership changes, and even a high-profile public bidding war with U.S. rival Pfizer (PFE). Although Novo’s blockbuster Ozempic enjoyed a four-year head start over Lilly’s Mounjaro, Lilly has now pulled ahead in U.S. prescriptions.

Novo’s struggles to keep up with demand also allowed compounding pharmacies to step in, chipping away at its market share and making 2025 one...

Fundamentals

See More
  • Market Capitalization, $K 1,018,887,616
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.37
  • Price/Sales 22.60
  • Price/Cash Flow 75.66
  • Price/Book 42.69

Options Overview Details

View History
  • Implied Volatility 29.92% (+0.80%)
  • Historical Volatility 23.45%
  • IV Percentile 23%
  • IV Rank 12.00%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Expected Move (DTE 5) 24.12 (2.24%)
  • Put/Call Vol Ratio 0.71
  • Today's Volume 33,851
  • Volume Avg (30-Day) 41,589
  • Put/Call OI Ratio 0.94
  • Today's Open Interest 382,078
  • Open Int (30-Day) 426,492
  • Expected Range 1,053.63 to 1,101.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.48
  • Number of Estimates 7
  • High Estimate 8.72
  • Low Estimate 7.00
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +40.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
977.12 +10.30%
on 12/10/25
1,099.05 -1.94%
on 11/28/25
-26.59 (-2.41%)
since 11/26/25
3-Month
716.08 +50.51%
on 09/29/25
1,111.99 -3.08%
on 11/26/25
+353.21 (+48.75%)
since 09/26/25
52-Week
623.78 +72.78%
on 08/08/25
1,111.99 -3.08%
on 11/26/25
+283.61 (+35.71%)
since 12/26/24

Most Recent Stories

More News
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026

Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.

NVO : 52.40 (-0.30%)
LLY : 1,077.75 (+0.07%)
Sector Rotation: 2 Smart Money Moves for 2026

Investors are rotating capital into communication services and healthcare stocks as falling interest rates create new opportunities for growth and income.

NFLX : 94.47 (+0.89%)
META : 663.29 (-0.64%)
GOOG : 314.96 (-0.22%)
XLV : 156.05 (+0.16%)
TMO : 580.74 (+0.28%)
LLY : 1,077.75 (+0.07%)
XLC : 117.97 (-0.10%)
UNH : 331.83 (+1.30%)
DIS : 113.56 (-0.80%)
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?

As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?

NVO : 52.40 (-0.30%)
$SPX : 6,929.94 (-0.03%)
LLY : 1,077.75 (+0.07%)
PFE : 25.09 (+0.24%)
3 Reasons Investors Love Eli Lilly (LLY)

3 Reasons Investors Love Eli Lilly (LLY)

LLY : 1,077.75 (+0.07%)
2 Profitable Stocks with Exciting Potential and 1 Facing Challenges

2 Profitable Stocks with Exciting Potential and 1 Facing Challenges

ARES : 168.73 (-0.20%)
UNP : 233.44 (-0.68%)
LLY : 1,077.75 (+0.07%)
Why Eli Lilly (LLY) Stock Is Trading Up Today

Why Eli Lilly (LLY) Stock Is Trading Up Today

LLY : 1,077.75 (+0.07%)
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound

LLY : 1,077.75 (+0.07%)
Lilly to participate in J.P. Morgan Healthcare Conference

INDIANAPOLIS , Dec. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 44 th Annual J.P. Morgan Healthcare Conference, Jan. 12-15, 2025. David A. Ricks, Lilly...

LLY : 1,077.75 (+0.07%)
3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

SYK : 354.22 (-0.15%)
JNJ : 207.63 (-0.07%)
LLY : 1,077.75 (+0.07%)
AMGN : 332.93 (-0.31%)
Pfizer Adds to Its Big Bet on Weight Loss Drugs

A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.

NVO : 52.40 (-0.30%)
JNJ : 207.63 (-0.07%)
LLY : 1,077.75 (+0.07%)
REGN : 784.97 (+0.16%)
PFE : 25.09 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,096.42
2nd Resistance Point 1,088.90
1st Resistance Point 1,083.33
Last Price 1,077.75
1st Support Level 1,070.24
2nd Support Level 1,062.72
3rd Support Level 1,057.15

See More

52-Week High 1,111.99
Last Price 1,077.75
Fibonacci 61.8% 925.49
Fibonacci 50% 867.89
Fibonacci 38.2% 810.28
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar